North East and North Cumbria
ICS Formulary
6 Endocrine system
06-04-01-01 Raloxifene
Raloxifene Hydrochloride
Formulary
For use on the advice of specialists in the prevention and treatment of osteoporosis where alternative treatments are inappropriate.
NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (Not Approved)
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Links
British Menopause Society update on HRT supply
MHRA Drug Safety Update (Aug 2019): Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping.
NENC ICB - Management of the Menopause
NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (Not Approved)
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
NTAG Endocrine System Recommendations
Key
Full Site